Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23106074 | 0.91 | CTSK (0.50) | CTSKCTSSCA2BACE1MEN1 | |
| SCHEMBL17902991 | 0.90 | CTSS (0.52) | CTSKCTSSCA2BACE1MEN1 | |
| SCHEMBL17581833 | 0.90 | CTSS (0.52) | CTSKCTSSCA2BACE1MEN1 | |
| SCHEMBL12283739 | 0.90 | CTSS (0.52) | CTSKCTSSCA2BACE1MEN1 | |
| SCHEMBL13436631 | 0.90 | CTSS (0.52) | CTSKCTSSCA2BACE1MEN1 | |
| SCHEMBL14012280 | 0.90 | CTSS (0.52) | CTSKCTSSCA2BACE1MEN1 | |
| SCHEMBL28342732 | 0.89 | CTSK (0.48) | CTSKCTSSCA2BACE1MEN1 | |
| SCHEMBL17209941 | 0.89 | CTSK (0.48) | CTSKCTSSCA2BACE1MEN1 | |
| SCHEMBL20177212 | 0.88 | MMP1 (0.43) | CTSKCTSSMMP1MMP3MMP9 | |
| SCHEMBL23998665 | 0.86 | CTSS (0.51) | CTSKCTSSCA2BACE1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2023066314-A1 | BICYCLIC PEPTIDE LIGAND FOR NECTIN-4 AND USE THEREOF | 海思科医药集团股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | CTSK 571/4885CTSS 1188/4885MMP1 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.